Egalet jumps on data for abuse-deterrent morphine

Egalet Corp. (NASDAQ:EGLT) climbed $1.18 (24%) to $6.11 on topline data from a human abuse liability study showing that 60 mg Egalet-001, an abuse-deterrent, extended-release, oral formulation of morphine, demonstrated significantly lower abuse potential compared to 60 mg manipulated MS Contin morphine sulfate controlled-release oral tablets from Purdue Pharma L.P. (Stamford, Conn.).

Egalet-001 employs the company's Guardian technology, which includes an injection molding process to render the product difficult to chew or manipulate. ...